Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Eisai Posts First Ever Net Loss Due To Heavy Investment

This article was originally published in PharmAsia News

Executive Summary

TOKYO - Eisai posted losses in net income for fiscal 2007 due to heavy investment in oncology research and development through recent acquisitions. Eisai's losses were a first since it became a listed company in 1961
Advertisement

Related Content

Eisai’s Aciphex Cleared In U.S. For Adolescent GERD, Matching Broader Label Of Other PPIs
Eisai’s Aciphex Cleared In U.S. For Adolescent GERD, Matching Broader Label Of Other PPIs
MHLW Approves Abbott’s Humira To Be Distributed By Eisai In Japan
MHLW Approves Abbott’s Humira To Be Distributed By Eisai In Japan
FDA Panel Backs Eisai/MGI's Aquavan - With Proviso
Eisai Strengthens Oncology Position With $3.9 Billion MGI Pharma Acquisition
Advertisement
UsernamePublicRestriction

Register

SC068552

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel